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Abstract
Background: An essential event during the replication cycle of HIV-1 is the integration of the reverse transcribed
viral DNA into the host cellular genome. Our former report revealed that HIV-1 integrase (IN), the enzyme that
catalyzes the integration reaction, is positively regulated by acetylation mediated by the histone acetyltransferase
(HAT) p300.
Results: In this study we demonstrate that another cellular HAT, GCN5, acetylates IN leading to enhanced 3’-end
processing and strand transfer activities. GCN5 participates in the integration step of HIV-1 replication cycle as
demonstrated by the reduced infectivity, due to inefficient provirus formation, in GCN5 knockdown cells. Within
the C-terminal domain of IN, four lysines (K258, K264, K266, and K273) are targeted by GCN5 acetylation, three of
which (K264, K266, and K273) are also modified by p300. Replication analysis of HIV-1 clones carrying substitutions
at the IN lysines acetylated by both GCN5 and p300, or exclusively by GCN5, demonstrated that these residues are
required for efficient viral integration. In addition, a comparative analysis of the replication efficiencies of the IN
triple- and quadruple-mutant viruses revealed that even though the lysines targeted by both GCN5 and p300 are
required for efficient virus integration, the residue exclusively modified by GCN5 (K258) does not affect this process.
Conclusions: The results presented here further demonstrate the relevance of IN post-translational modification by
acetylation, which results from the catalytic activities of multiple HATs during the viral replication cycle. Finally, this
study contributes to clarifying the recent debate raised on the role of IN acetylated lysines during HIV-1 infection.
Background
Integration of reverse transcribed HIV-1 DNA into the
cellular genome is catalyzed by the viral IN protein.
Even though in vitro integration can be solely driven by
IN, cellular cofactors are required to complete the reac-
tion in vivo. It was recently reported that the cellular
HAT p300 interacts with IN and regulates its function
through acetylation [1,2]. HATs are enzymes able to
transfer acetyl groups from acetyl coenzyme A (acetyl-
CoA) to specific lysine residues within the N-terminal
tails of nucleosomal histones, leading to chromatin
decondensation and transcriptional activation [3,4].
HATs can also acetylate non-histone substrates, such as
transcription factors and other nuclear proteins, as well
as cytoskeletal components, metabolic enzymes and sig-
nalling regulators in the cytoplasm [5]. Acetylation has
been reported to regulate the activity of these factors by
modulating DNA binding [6-8], protein-protein interac-
tions [9-12], protein stability [13-15], and subcellular
localization [16-19]. Growing evidence now indicates
that acetylation significantly participates in signaling
pathways ultimately regulating viral infectivity [20-26].
Among the viral factors functionally modulated by acet-
ylation is the HIV-1 protein Tat. Tat is acetylated at
lysine 28 by PCAF, while residues 50 and 51 are sub-
strates for p300/CBP and GCN5 [27-29]. Acetylation of
lysine 28 enhances the ability of Tat to recruit the P-
TEFb complex [28], while modification of lysine 50
leads to Tat dissociation from TAR RNA [28,30]. There-
fore, even though the final effect of acetylation is an
increased transactivation activity on the viral LTR pro-
moter, the modification of each individual lysine differ-
ently affects Tat functionality at the molecular level.
We have recently discovered that another HIV-1-
encoded protein, IN, is a substrate for p300-mediated
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any medium, provided the original work is properly cited.acetylation. Three lysine residues, located at positions
264, 266, and 273 in the C-terminal domain of IN, were
identified as the target sites for modification [1,2]. Acety-
lation by p300 was shown to increase both IN affinity for
DNA and strand transfer activity [1], thus suggesting a
potential role for this post-translational modification dur-
ing viral integration. The importance of IN acetylation
for HIV-1 replication was further highlighted by the find-
ing that the mutant virus, in which arginine substitutions
were introduced at p300-targeted IN lysines, integrated
less efficiently than the wild type [1].
Since proteins modified by acetylation are often sub-
strates for multiple HATs, we sought to investigate
whether IN might be acetylated by enzymes other than
p300. It has already been reported that MOZ and PCAF
(belonging to the MYST and GNAT families of HATs,
respectively) are incapable of efficiently acetylating the
IN C-terminal domain in vitro [2]. Therefore, in this
study, another member of the GNAT family, GCN5,
was examined. Here we demonstrate that GCN5 binds
and acetylates IN both in vitro and in vivo.G C N 5
expression is functionally relevant to HIV-1 infectivity
and specifically affects the integration process, likely by
modulating the catalytic activity of IN. Interestingly, the
four lysines targeted by GCN5 partially overlap with
those modified by p300 in the C-terminal domain of IN.
A comparative analysis of viral clones mutated at IN
lysines acetylated by GCN5o rp 3 0 0r e v e a l e dt h es a m e
replication defect at the step of integration, thus indicat-
ing common roles for the two HATs in regulating IN
function.
Results
HIV-1 IN is acetylated by GCN5
To examine whether IN is acetylated by GCN5, in vitro
acetylation assays were performed with recombinant IN
and GCN5, both purified as GST fusion proteins. Incuba-
tion of the single GST domain with GCN5 in the pre-
sence of [
14C]-acetyl-CoA, and subsequent protein
resolution by SDS-PAGE followed by autoradiography,
revealed a unique band at the same size as GST-GCN5,
corresponding to the auto-acetylation product of the
enzyme (Figure 1A, lane 1). Incubation of GST-IN with
GST-GCN5 resulted in two major radiolabeled bands,
the higher one corresponding to auto-acetylated GST-
GCN5 and the lower one to GST-IN (Figure 1A, lane 2),
thus demonstrating that GCN5 specifically acetylates IN
in vitro.
To define which region of IN is acetylated by GCN5,
GST-IN fragments with progressive deletions starting
from the C-terminus (as schematized in Figure 1C) were
used as substrates in in vitro acetylation assays, and the
corresponding acetylation signals in the autoradiograms
were evaluated by densitometric analysis (Figure 1B, left
histogram). GST-IN fragment 1-272 was acetylated to a
similar extent as full-length IN (Figure 1A, compare
lanes 2 and 3, and Figure 1B, left histogram). Acetylation
of fragment 1-263 (Figure 1A, lane 4) was reduced by
3 0 %( F i g u r e1 B ,l e f th i s t o g r a m ) ,w h i l eam o r es i g n i f i c a n t
decrease in the signal (ranging from 60% to 70%) was
observed using shorter fragments (1-243, 1-234 and 1-
212) (Figure 1A, lanes 5-7, and Figure 1B, left histogram).
These results indicated that IN is acetylated by GCN5
within the region located between amino acids 244 and
288. As schematically represented in Figure 1C, this
region contains five lysines at positions 244, 258, 264,
266, and 273 as possible targets for acetylation. There-
fore, in order to exclude that the reduced acetylation of
the deleted IN forms resulted from improper protein
folding, each of these lysines was replaced with an argi-
nine, an amino acid that cannot be acetylated and con-
serves a positively charged side chain. The resulting
mutants were then tested in vitro as substrates for GCN5
activity. In this experiment, IN was tagged with a 6× His
epitope in place of GST, in order to obtain better SDS-
PAGE resolution between acetylated GCN5 and IN
(Figure 1A, lane 8). As reported in the right histogram of
Figure 1B, densitometric analysis of radioactivity incor-
poration highlighted that the mutation of the individual
lysines 258, 264, 266, and 273 (Figure 1A, lanes 10-13)
caused a reduction in the acetylation level of IN ranging
from 40% to 50%, while no significant decrease in the sig-
nal was detected upon mutation of lysine 244 (Figure 1A,
lane 9). These data suggested that GCN5 acetylates IN at
residues 258, 264, 266, and 273. Notably, previous reports
demonstrated that another HAT, p300, acetylates lysines
264, 266, and 273 of IN [1,2]. To confirm that GCN5
acetylates lysine 258 in addition to the above-mentioned
residues, two mutant forms of IN were assayed for in
vitro acetylation: one containing mutations at the sites
acetylated by both GCN5 and p300 (IN K264,266,273R),
and the other carrying these same amino acidic substitu-
tions, with the additional mutation of lysine 258 specifi-
cally targeted by GCN5 (IN K258,264,266,273R). The
decrease in the radioactive signal detected with IN
K264,266,273R was similar to the one obtained with the
single-mutated forms (compare lane 14 with lanes 10-13
in Figure 1A, and right histogram of Figure 1B), while the
residual acetylation level of IN K258,264,266,273R
d r o p p e dt o2 0 %w i t hr e s p e c tt ow i l dt y p e( F i g u r e1 A ,
lane 15, and Figure 1B, right histogram). These results
demonstrated that GCN5 acetylates lysines 264, 266, and
273 of IN, also targeted by p300, and lysine 258 as a spe-
cific site of modification.
Next, we investigated whether IN is also acetylated by
GCN5 in vivo. Codon-optimized Flag-IN [31] was
expressed in HEK 293T cells, alone or together with
HA-GCN5 wild type or mutated in the catalytic domain
Terreni et al. Retrovirology 2010, 7:18
http://www.retrovirology.com/content/7/1/18
Page 2 of 16Figure 1 HIV-1 IN is acetylated by GCN5 in vitro. (A) Autoradiography (upper panels) and Coomassie blue staining (lower panels) of in vitro
acetylation assay with recombinant GST-GCN5 and IN wild type or mutant proteins. Lanes 1-7: GST fusion IN proteins; lanes 8-15: 6× His-tagged
IN proteins. In the Coomassie panels, IN proteins used as acetylation substrates are indicated by asterisks; in the autoradiograms, IN proteins
found positive for GCN5-mediated acetylation are indicated in the same way. Presented results are representative data from triplicate in vitro
acetylation assay experiments. (B) Results of densitometric analysis of autoradiograms derived from three independent experiments (means ±
standard errors of the means [SEM]) expressed as percent wild type IN acetylation. (C) Schematic representation of IN proteins used for the
acetylation assays. The positions of lysines in the C-terminal domain of IN are indicated. Lysines positive for acetylation are shown in red.
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Page 3 of 16(Y260A/F261A) [32]. Immunoprecipitation of IN and
subsequent detection by Western blotting with an anti-
body specific to acetylated lysines revealed the highest
acetylation signal in the sample corresponding to IN co-
expressed with wild type GCN5 (Figure 2A, upper
panel, lane 3). Conversely, expression of IN alone or
together with catalytically inactive GCN5 resulted in a
lower acetylation signal, likely derived from the activity
of endogenous HATs (Figure 2A, upper panel, lanes 2
and 4). In this experiment, the total amounts of immu-
noprecipitated IN and the expression levels of wild type
and mutant GCN5 were verified by Western blot analy-
sis with anti-Flag and anti-HA antibodies, respectively
(Figure 2A, middle and lower panels).
Figure 2 IN is acetylated by GCN5 in vivo. (A) Extracts from HEK 293T cells transfected with the indicated plasmids were immunoprecipitated
using anti-Flag antibody and analyzed by Western blotting with anti-acetyl-lysine antibody (upper panel) or anti-Flag antibody (middle panel).
Lower panel: cell extracts immunoblotted with anti-HA antibody. (B) Acetylated BSA and peptides corresponding to IN amino acids 260-281,
either chemically acetylated at lysines 264, 266, and 273, or not acetylated, were blotted onto a nitrocellulose filter and incubated with anti-
acetylated IN antibody. (C) Left panels (lanes 1-4): extracts from HEK 293T cells transfected with the indicated plasmids were immunoprecipitated
using anti-Flag antibody and analyzed by Western blotting with anti-acetylated IN antibody (top panel) or anti-Flag antibody (bottom panel).
Right panels (lanes 5-8): extracts from HEK 293T cells transfected with the indicated plasmids analyzed by Western blotting with anti-acetylated-
IN antibody (top panel) or anti-Flag antibody (bottom panel). (D) Extracts from HEK 293T cells transfected with the indicated plasmids analyzed
by Western blotting with anti-acetylated-IN antibody (upper panel), anti-Flag antibody (middle panel), or anti-HA antibody (lower panel).
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Page 4 of 16Detection of in vivo IN acetylation by a novel anti-
acetylated IN antibody
To confirm the in vitro observation that IN is a substrate
for both GCN5 and p300, an antibody specific to acety-
lated IN was produced by using an IN-derived peptide
for immunization. The IN-derived peptide was chemi-
cally acetylated at lysines 264, 266, and 273, which are
targeted in common by the two HATs (see the Methods
section). As shown in Figure 2B, the purified antibody
specifically recognized the acetylated IN peptide in dot
blot experiments, while no cross-reactivity was detected
with the unmodified peptide or acetylated BSA. This
antibody allowed detecting basal levels of IN acetylation
by endogenous HATs following immunoprecipitation
(Figure 2C, top-left panel, lane 1); additionally, high levels
of IN acetylation were detected from cells overexpressing
p300 (Figure 2C, top-left panel, lane 2). This result is
consistent with our previous study showing that p300
mediates IN acetylation in vivo at positions 264, 266, and
273 [1]. Conversely, no signal, expressed either alone or
together with p300 (Figure 2C, top-left panel, lanes 3 and
4), was detected with IN K264,266,273R, thus revealing
the high specificity of the antibody. In this experiment,
the amount of IN (wild type or mutated) immunoprecipi-
tated in each sample was verified by Western blotting
with an anti-Flag antibody (Figure 2C, bottom-left panel).
The anti-acetylated IN antibody was also used for direct
Western blot analysis of cell lysates, producing a strong
acetylation signal in the sample corresponding to IN co-
expressed with p300 (Figure 2C, top-right panel, lane 6).
Therefore, the newly develop e da n t i b o d ys h o w e dh i g h e r
sensitivity than the standard anti-acetyl-lysine antibodies,
which require an immunoprecipitation step to reveal IN
acetylation. Given the high specificity and sensitivity of
the anti-acetylated IN antibody, it was used to confirm
the in vivo acetylation of IN by GCN5, as well as the
mapping of the in vitro targeted lysines. As shown in the
upper panel of Figure 2D, extracts from cells co-expres-
sing wild type IN and GCN5 revealed a remarkable signal
corresponding to IN acetylation (lane 4); while, consis-
tent with the data reported in Figure 2C (top right panel,
lane 5), acetylation of the viral enzyme by endogenous
HATs was almost undetectable (lane 1). Conversely, no
signal with triple- and quadruple-mutant IN, expressed
either alone (lanes 2 and 3) or together with GCN5
(lanes 5 and 6) was detected. In this experiment, Western
blot analysis of the cell lysates was also performed with
anti-Flag and anti-HA antibodies to control the levels of
exogenously expressed proteins (Figure 2D, middle and
lower panels). Taken together, these data demonstrated
that IN is acetylated by GCN5 both in vitro and in vivo,
and the targeted lysines are located in the C-terminal
domain at positions 258, 264, 266, and 273.
IN interacts with GCN5
Since IN is acetylated by GCN5, the interaction between
these two factors was investigated. To this aim, HEK
293T cells were transfected with Flag-IN together with
HA-GCN5 wild type or mutated in the catalytic domain.
After immunoprecipitation with an anti-Flag antibody,
both wild type and mutant GCN5 were found to co-pre-
cipitate with IN, as demonstrated by Western blot ana-
lysis using an anti-HA antibody (Figure 3A, upper panel,
lanes 3 and 4). Accordingly, in the reciprocal experi-
ment, where immunoprecipitation was performed with
an anti-HA antibody, IN was found to associate with
GCN5 (both wild-type and mutant forms) (Figure 3B,
upper panel, lanes 3 and 4). In both experiments, the
total amounts of immunoprecipitated proteins and the
expression levels of IN and GCN5 were verified by Wes-
tern blotting (Figures 3A and 3B, middle and lower
panels).
To map the region of IN mediating the interaction
with GCN5, pull-down assays were carried out between
GST-GCN5 immobilized on glutathione-Sepharose
beads and IN deletion mutants labeled with [
35S]-Met
by in vitro translation. As shown in Figure 3C, the affi-
nities of IN fragments 1-272 and 1-263 to GST-GCN5
(13% binding efficiency) were similar to that of full-
length IN (16% binding efficiency). Conversely, the
GCN5/IN interaction significantly decreased using frag-
ments containing further deletions towards the N-termi-
nus (1-243 and 1-234). These results indicated that the
C-terminal region of IN located between amino acids
244 and 288 is involved in binding to GCN5.
Acetylation by GCN5 increases IN catalytic activity in vitro
To explore the effect of GCN5-mediated acetylation on
the catalytic activity of IN, constitutively acetylated
recombinant IN was produced by exploiting the “teth-
ered catalysis” approach [33,34]. This method allows the
production of a constitutively acetylated protein by
tethering the factor of interest to the catalytic domain of
a specific HAT enzyme. Based on this approach, as
schematized in Figure 4A, a chimeric construct was gen-
erated where 6× His-tagged IN was fused at its C-term-
inal end with the HAT domain of GCN5 (amino acids
6-300). To obtain a control that cannot be acetylated,
the same chimera was constructed using the inactive
mutant of GCN5 Y260A/F261A. In addition, a sequence
coding for Tobacco Etch Virus (TEV) protease recogni-
tion site was inserted between IN and GCN5 coding
sequences to allow for the separation of the two
domains. The fusion proteins expressed from the two
chimeric constructs were purified, digested with TEV
protease, and the acetylation levels of the resulting IN
proteins analyzed by Western blotting with an anti-
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Page 5 of 16Figure 3 IN interacts with GCN5 both in vitro and in vivo. (A) Extracts from HEK 293T cells transfected with the indicated plasmids were
immunoprecipitated using anti-Flag antibody and analyzed by Western blotting with anti-HA antibody (upper panel) or anti-Flag antibody
(middle panel). Lower panel: extracts immunoblotted with anti-HA antibody. (B) Extracts from HEK 293T cells transfected with the indicated
plasmids were immunoprecipitated using anti-HA antibody and analyzed by Western blotting with anti-Flag antibody (upper panel) or anti-HA
antibody (middle panel). Lower panel: extracts immunoblotted with anti-Flag antibody. (C) Autoradiography and Coomassie Blue staining of in
vitro binding assays with GST-GCN5 and
35S-IN or the indicated
35S-IN fragments. The histogram represents the results of three independent
experiments (means ± SEM), where the amounts of bound proteins are expressed as percentages of the corresponding radiolabeled inputs.
Statistical significance of the binding percentages was calculated by using the Student’s two-sided t test. Asterisks directly above bars indicate
differences in binding efficiency to GST-GCN5 between IN deleted forms and full-length IN. **, P < 0,01; *, P < 0,05. Conversely, where asterisks
are not present, values obtained did not significantly differ (P > 0,05) from those obtained with control, non-silenced cells.
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Page 6 of 16acetyl-lysine antibody. IN derived from the wild type
GCN5 fusion scored positive for acetylation, while no
significant signal was detected with IN derived from the
GCN5 mutant chimera (Figure 4B, top panel, compare
lanes 1 and 3 with lanes 2 and 4). In this experiment,
the levels of loaded proteins were verified by incubating
the same membrane with an antibody directed against
IN (Figure 4B, bottom panel).
Constitutively acetylated recombinant IN and the non-
acetylated control were tested in vitro for 3’-end proces-
sing and strand transfer activities. In the 3’-end
processing reaction, recombinant IN was incubated with
a[
32P]-labeled DNA substrate (S) and the excision of 2
nucleotides evaluated by measuring the radioactive sig-
nal of the shorter product (P). In Figure 4C the com-
parative analysis by densitometry of the bands
corresponding to the 3’-end processed template, indi-
cated that acetylated IN (100 ng in lane 1 and 200 ng in
lanes 3) was two- to three-fold more active than non-
acetylated controls (lanes 2 and 4 respectively). In the
strand transfer assay, a [
32P]-labeled oligonucleotide was
used as a substrate (S) and IN activity was evaluated by
Figure 4 GCN5-mediated acetylation increases the catalytic activity of IN. (A) Schematic representation of IN-GCN5 tethered catalysis
constructs. Full-length IN, tagged with a N-terminal 6× His epitope, is fused in frame with TEV proteolytic site and cloned upstream of the 6-300
amino acid region of wild type GCN5 (IN-HAT wt) or its catalytically inactive allele (IN-HAT mut). (B) 1 μg and 2 μg of IN derived from IN-HAT wt
(lanes 1 and 3, respectively), or 1 μg and 2 μg of IN derived from IN-HAT mut (lanes 2 and 4, respectively) were analyzed by Western blotting
with anti-acetyl-lysine antibody (top panel) or anti-IN antibody (bottom panel). (C) 3’ -end processing activity of IN derived from IN-HAT wt (lane
1: 100 ng; lane 3: 200 ng) or IN-HAT mut (lane 2: 100 ng; lane 4: 200 ng). Lane 5: DNA substrate; lane 6: DNA substrate with 40 ng of 6× His-
tagged IN. (D) Strand transfer activity of IN derived from IN-HAT wt (lane 1: 100 ng; lane 3: 200 ng) or IN-HAT mut (lane 2: 100 ng; lane 4: 200
ng). Lane 5: DNA substrate; lane 6: DNA substrate with 40 ng of 6× His-tagged IN. In (C) and (D), the DNA substrate (S) and the catalytic
products (P) are indicated.
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Page 7 of 16measuring the radioactive signal derived from the ladder
of higher molecular weight products (P). Constitutively
acetylated IN, at two different doses (100 ng and 200
ng), was more active than non-acetylated IN (Figure 4D,
compare lanes 1 and 3 with lanes 2 and 4). This was
consistent with the 3’-end processing results. Finally,
densitometric analysis of the autoradiograms indicated
that the two amounts of acetylated IN were five- to ten-
fold more active than the corresponding non-acetylated
controls.
Taken together, these results demonstrated that
GCN5-mediated acetylation enhances the catalytic activ-
ity of IN in vitro.
HIV-1 infectivity is reduced in GCN5 knockdown cells
In order to assess the physiological relevance of the IN/
GCN5 interaction during HIV-1 replication cycle, viral
infectivity upon GCN5 depletion in target cells was
monitored. Transient knockdown of GCN5 expression
was obtained in HeLa cells using a specific short inter-
fering RNA (siRNA), while stably silenced HEK 293T
cell clones were selected after transduction with a lenti-
viral vector (pGIPZ from Open Biosystems, Inc.) encod-
ing a short hairpin RNA (shRNA) targeting GCN5
(GCN5 shRNAmir). As a control for the transient
knockdown experiments, HeLa cells were transfected
with a non-targeting siRNA (unrelated to any human
genomic sequence), while stable silencing experiments
were checked by using two HEK 293T polyclonal cell
lines, one expressing a mismatched, non-targeting
GCN5 shRNAmir (GCN5 shRNAmir mut) and the
other carrying an empty pGIPZ vector. As shown in the
top panels of Figure 5A, siRNA- and shRNAmir-
mediated knockdown reduced GCN5 expression to a
similar extent. Silenced cells were then infected with an
env-deleted, VSV-G pseudotyped NL4.3 virus expressing
the luciferase reporter gene (indicated hereafter as
NL4.3-Luc), and luciferase activity was measured 48
hours after infection. As shown in Figure 5B, a two- to
three-fold reduction in luciferase activity was detected
in both transiently and stably silenced cells, thus indicat-
ing that knockdown of GCN5 expression in target cells
reduces HIV-1 infectivity. To determine which step of
viral replication was affected by GCN5 depletion, cells
were collected at various time points after infection, and
measurements of the different HIV-1 DNA species were
performed by real time quantitative PCR (RT-Q-PCR).
Total HIV-1 DNA was quantified with the use of pri-
mers annealing to the luciferase reporter gene, in order
to avoid cross-reaction with the integrated pGIPZ lenti-
viral vectors present in stably transduced cell lines. As
shown in Figure 5C, no significant alterations in total
HIV-1 DNA levels were detected in cells either transi-
ently or stably silenced, thus indicating that reverse
transcription was not affected by the reduction of GCN5
expression. SiRNA-treated cells were analyzed 48 hours
post-infection by Alu-LTR nested PCR to detect inte-
grated HIV-1 DNA, while stable knockdown cell clones
were processed two weeks after infection using primers
specific to the luciferase gene. This was necessary in
order to dilute non-integrated HIV-1 DNA and avoid
cross-reaction with the integrated pGIPZ lentiviral vec-
tors. Proviral DNA was about two-fold less in all GCN5
knockdown cells, either treated with siRNA or trans-
duced with shRNAmir-encoding lentiviral vectors (Fig-
ure 5D). Finally, a two-fold increase in the amount of
two-LTR circles was detected in both stably and transi-
ently silenced cells (Figure 5E). Since the increase in
two-LTR circles often correlates with a defect at the
step of integration [35], these data are collectively con-
sistent with reduced integration efficiency in GCN5
knockdown cells.
Mutations at IN acetylation sites cause a defect in HIV-1
replication at the integration step
Since the IN lysines acetylated by GCN5 partially over-
lap with those targeted by p300, a comparative analysis
was performed to evaluate the role of these residues
during the HIV-1 replication cycle. To this aim, single-
round infections were performed, using env-deleted
NL4.3-Luc viruses expressing either IN K264,266,273R
(NL4.3-Luc-3mut), or IN K258,264,266,273R (NL4.3-
Luc-4mut). Luciferase activity was measured 48 hours
after infection, revealing an average five-fold reduction
in infectivity for both mutant viruses as compared to
wild type (Figure 6A). To determine which step of viral
replication was affected by the lysine-to-arginine substi-
tutions, DNA was extracted from cells at several time
points after infection and the different HIV-1 DNA spe-
cies were measured by RT-Q-PCR. Infection with
NL4.3-Luc-3mut and 4mut, as well as with wild type
virus, resulted in similar levels of total HIV-1 DNA at
24 hours post-infection (Figure 6B), indicating that
reverse transcription was not affected by the amino
acidic substitutions. Integrated HIV-1 DNA was quanti-
fied at 48 hours post-infection by Alu-LTR nested PCR,
showing a five-fold reduction in the number of pro-
viruses for both mutant clones with respect to wild type
(Figure 6C). These data indicated decreased integration
efficiency upon mutation of IN lysines targeted by acety-
lation. Consistently, a three-fold increase in the amount
of two-LTR circles was detected at 24 hours post-infec-
tion with both NL4.3-Luc-3mut and 4mut (Figure 6D),
confirming a specific defect at the step of integration
and no alterations during viral nuclear import.
To investigate the role of IN acetylated lysines during
HIV-1 replication in a T-cell line, two NL4.3-derived
clones were generated, expressing either the triple- or
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Page 8 of 16Figure 5 GCN5 depletion in infected cells reduces HIV-1 integration.( A )L e f tp a n e l s :e x t r a c t sf r o ms i R NA-treated Hela cells analyzed by
Western blotting with anti-GCN5 antibody (top) or anti-a-tubulin antibody (bottom). Lane 1: cells transfected with non-targeting siRNA (Ctrl
siRNA); lane 2: cells transfected with GCN5-targeting siRNA (siGCN5). Right panels: extracts from stable GCN5 knockdown HEK 293T cell clones or
control cells immunoblotted with anti-GCN5 antibody (top panel) or anti-a-tubulin antibody (bottom panel). Lane 3: untransduced HEK 293T
cells; lane 4: HEK 293T cells carrying empty pGIPZ vector; lane 5: HEK 293T cells expressing mutant, non-targeting GCN5 shRNAmir; lanes 6-8: HEK
293T clones (Cl8, Cl9 and Cl13) expressing GCN5 shRNAmir. (B) siRNA-treated Hela cells (left histogram) or HEK 293T cells stably transduced with
pGIPZ lentiviral vectors (right histogram) were infected with NL4.3-Luc and analyzed for luciferase activity 48 hours after infection. The
histograms represent percentages of luciferase activity relative to control, non-silenced cells. Means ± SEM from three independent experiments
are reported. (C-E) Total DNA extracted from siRNA-treated HeLa cells (left histograms) or HEK 293T cells stably transduced with pGIPZ lentiviral
vectors (right histograms) was analyzed by RT-Q-PCR for total HIV-1 DNA (C), integrated HIV-1 DNA (D), and two-LTR circles (E). In (C-E), results
are presented as percentages relative to control, non-silenced cells. Reported values are means ± SEM from three independent experiments.
Statistical significance values shown in (B-E) were calculated by using the Student’s two-sided t test. Asterisks directly above bars indicate
differences between knockdown and control, non-silenced cells. ***, P < 0,001; **, P < 0,01; *, P < 0,05. Conversely, where asterisks are not
present, values obtained did not significantly differ (P > 0,05) from those obtained with control, non-silenced cells.
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Page 9 of 16quadruple-mutant IN (NL4.3-3mut and NL4.3-4mut,
respectively). One million CEM T-cells were infected
with the resulting viruses using two different amounts
of p24 antigen (10 ng or 1 ng). Viral replication was fol-
lowed by measuring HIV-1 reverse transcriptase (RT)
activity in the culture supernatants every three days over
a period of 21 days. As shown in Figure 6E, cells
infected with the higher viral load (10 ng of p24) of wild
type virus showed a peak of HIV-1 replication around
day 9 post-infection. Conversely, infections with the
same amounts of NL4.3-3mut and -4mut resulted in
delayed peaks at day 12. Notably, at the infectivity peak,
the RT amounts produced by both mutant HIV-1 clones
were approximately half of that obtained with wild type
virus. By using the lower viral load (1 ng of p24), the
replication curve of wild type virus started to raise quite
steeply around day 12 post infection, while for both
mutant clones the curves started to appear at day 15.
Detectable RT production was observed for both mutant
viruses at day 18, thus with 6 days of delay compared to
the kinetics of the wild type virus (Figure 6F). In
conclusion, mutations introduced in the virus at IN
acetylation sites targeted by both GCN5 and p300
(K264, K266, and K273), or additional mutation at lysine
258 specifically acetylated by GCN5 in vitro, determined
similar decreases in viral integration and infectivity.
Discussion
The results presented in this study reveal that GCN5 is
a novel HAT which interacts with IN. GCN5 binding to
the C-terminal domain of IN leads to the acetylation of
IN at lysines 258, 264, 266 and 273, located within the
same region required for the two proteins to interact.
We have recently demonstrated that the carboxy termi-
nus of IN is a substrate for another cellular HAT, p300,
which acetylates IN lysines at positions 264, 266, and
273 [1], a finding that was also later confirmed by Top-
per and coworkers [2]. Therefore, based on previous
and present studies, three IN lysines (K264, K266, and
K273) are acetylated by both HATs, while lysine 258
appears to be specifically targeted by GCN5. Our map-
ping of the HAT-interacting regions of IN based on
Figure 6 Mutations at IN acetylation sites cause a replication defect at the step of integration. (A) HEK 293T cells infected with NL4.3-
Luc/IN WT, NL4.3-Luc/IN K264,266,273R, or NL4.3-Luc/IN K258,264,266,273R were analyzed for luciferase activity 48 hours after infection. (B-D)
Total DNA extracted from HEK 293T cells infected with the same viral clones as in (A) was analyzed by RT-Q-PCR for total HIV-1 DNA at 24 hours
after infection (B), integrated HIV-1 DNA at 48 hours after infection (C) and two-LTR circles at 24 hours after infection (D). In (A-D), results are
presented as percentages relative to cells infected with NL4.3-Luc/IN WT virus. Reported values are means ± SEM from three independent
experiments. Statistical significance values shown in (A-D) were calculated by using the Student’s two-sided t test. Asterisks directly above bars
indicate differences between cells infected with mutant viruses and cells infected with wild type virus. ***, P < 0,001; **, P < 0,01. Conversely,
where asterisks are not present, values obtained did not significantly differ (P > 0,05) from those obtained with cells infected with wild type
virus. (E) RT activity detected in the culture supernatants of CEM cells at different time points after infection with NL4.3/IN WT, NL4.3/IN
K264,266,273R, or NL4.3/IN K258,264,266,273R. (F) Infections performed as in (E), using 10-fold lower viral loads.
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which presented two models of full-length IN com-
plexed with GCN5 and p300 [36]. Both models predict
that the IN C-terminal tail located between amino acids
271 and 288, due to its high flexibility, could easily
adapt to the binding pocket of GCN5, as well as to that
of p300 (Figure 7). Interestingly, lysine 273 is included
in this unstructured region and is therefore expected to
be the residue most prone to acetylation. In fact, since
lysines 264 and 266 are located in close proximity to a
sandwich of two three-stranded antiparallel b-sheets,
their binding and acetylation would require a more
complex unfolding of this stable secondary structure.
Based on this model, we may hypothesize that IN lysine
273 is the first residue contacted and acetylated by the
HAT enzyme, whether GCN5 or p300. This event might
in turn induce a conformational change in the C-term-
inal portion of IN, which could facilitate the modifica-
tion of the other two lysines. This hypothesis is also
compatible with the data reported by Topper and cow-
orkers, demonstrating a hierarchy of reactivity between
the three residues modified by p300, with lysine 273 as
the key site targeted for acetylation [2].
A comparative analysis, aimed at establishing the roles
of the two HATs during the HIV-1 replication cycle,
revealed that the mutant viruses expressing either IN
K264,266,273R or IN K258,264,266,273R exhibited the
same replication deficiency, specifically affecting the step
of integration. These results indicated that acetylation of
IN C-terminal lysines 264, 266, and 273 is required for
maximal HIV-1 integration efficiency, while acetylation
of lysine 258, although observed in vitro, does not
appear to play any significant role during infection.
Proteins modified by acetylation, including viral fac-
tors, are often targeted by multiple HATs in a redun-
dant manner. For instance, HIV-1 Tat is acetylated at
lysines 50 and 51 by p300/CBP and GCN5, leading in
both cases to an increased transactivation activity of the
modified protein on the viral LTR promoter [27-30].
The action of two different HATs on common sites of
the same substrate may be ascribed to the importance
of acetylation for the functionality of the target protein.
However, in the case of IN, the reduced viral integration
capacity detected in GCN5 knockdown cells indicated
that endogenous p300 is not able to fully compensate
for the lack of GCN5 so as to completely restore HIV-1
infectivity.
The role of IN acetylation at lysines 264, 266 and 273
during the HIV-1 replication cycle has been the subject
of a recent debate. Our former study showed that the
replication level of a HIV-1BRU clone expressing a triple-
mutant Flag-tagged IN (Flag-IN K264,266,273R) was
severely impaired, and that the replication deficiency
was specifically due to a block at the integration step
[1]. In subsequent reports, the untagged triple-mutant
virus showed either no replication defect [2], or a five-
fold infectivity decrease in single-round infections [37].
Moreover, by using a genetic assay where integration
was evaluated through the number of cell clones con-
taining proviruses, one report [2] detailed almost half
decreased integration efficiency, while the other [37]
indicated a 14-fold lower residual integration rate. In
Figure 7 Three-dimensional models of IN complexes with GCN5 and p300. (A) Three-dimensional model of the IN/GCN5 complex. IN is
represented in green and GCN5 in light grey. (B) Three-dimensional model of the IN/p300 complex. IN is represented in green and p300 in light
grey. In (A) and (B), the three lysine residues in the C-terminal domain of IN that are acetylated by both GCN5 and p300 (Lys 264, Lys 266, and
Lys 273) are shown in yellow. GCN5 and p300 are rendered as surfaces, while IN as a cartoon to highlight the C-terminal unfolded portion
which inserts in the binding pockets of the two HATs.
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round infections with HIV-1 clones encoding IN either
mutated at the positions targeted by both GCN5 and
p300 (IN K264,266,273R), or carrying an additional
lysine-to-arginine substitution at the site specifically
modified by GCN5 (IN K258,264,266,273R). In multiple-
round replication experiments, both mutant clones
showed reduced virus production and delays in the
peaks of infectivity with respect to wild type. The discre-
pancy of these findings with the data reported by Top-
per et al. [2] might be due to the different time-courses
of analyses: although working in the same experimental
conditions (10 ng of p24 antigen per 1× 10
6 CEM cells),
the detection of RT activity in the culture supernatants
over a period of 21 days allowed us to monitor the peak
of HIV-1 replication, while Topper and coworkers ter-
minated the replication curve before the highest point
of viral infectivity was reached (at 12 days post
infection).
Moreover, consistent with Apolonia et al. [37], we
detected a five-fold infectivity decrease in single-round
replication assays performed with IN triple- and quadru-
ple-mutant viruses. The five-fold infectivity decrease
paralleled a five-fold reduction in the number of pro-
viruses, as measured by RT-Q-PCR. Taken together, the
results presented in all the different reports suggest that
acetylation of IN C-terminal lysines 264, 266, and 273
represents a mechanism which, by finely regulating the
integration process, contributes to determine the effi-
ciency of HIV-1 replication.
Identification of lysines 258, 264, 266, and 273 as the
targets of GCN5 activity on IN does not exclude that
additional residues might be acetylated, as indicated by
the residual acetylation level of the quadruple-mutant
IN (Figure 1A, lane 15). Finally, IN could also be subject
to different post-translational modifications, such as
methylation, sumoylation, or ubiquitination [38-41],
which might open up new mechanisms of modulation
of IN function.
Conclusions
This study demonstrates that, in addition to the formerly
reported p300, another HAT, GCN5, acetylates the
C-terminal domain of IN. Similar to p300, GCN5-
mediated acetylation is required for efficient viral integra-
tion, thus reinforcing the role of this post-translational
modification for HIV-1 replication.
Methods
Plasmids
Construction of pGEX-IN has already been described
[1]. pcDNA3-HA-IN was obtained by subcloning IN
sequence from pGEX-IN plasmid into pcDNA3-HA vec-
tor. pGEX-IN and pcDNA3-HA-IN deletion mutants
were produced by PCR amplification of IN with primers
specific to the deleted versions. pASK-IBA37-IN was
constructed by subcloning IN sequence from pGEX-IN
plasmid into pASK-IBA37 vector (IBA GmbH, Göttin-
gen, DE). pFlag-IN codon optimized (c.o.) was kindly
provided by A. Engelman. pASK-IBA37-IN point
mutants and pFlag-IN c.o. K264,266,273R or
K258,264,266,273R were obtained by PCR-based site-
directed mutagenesis starting from the corresponding
plasmids encoding wild type IN.
pGEX-GCN5 was a kind gift of M. Benkirane. pGEX-
GCN5 deletion mutants were produced by PCR amplifi-
cation of GCN5 with primers specific to the truncated
forms. pcDNA3-HA-GCN5 was constructed by subclon-
ing GCN5 sequence from pGEX-GCN5 plasmid into
pcDNA3-HA vector. pcDNA3-HA-GCN5 (Y260A/
F261A) [32] was obtained by PCR-based site-directed
mutagenesis starting from the plasmid encoding wild
type GCN5.
For production of IN-GCN5 tethered catalysis con-
structs, the sequence coding for the 6-300 amino acid
region of GCN5 was amplified by PCR from pcDNA3-
HA-GCN5 or pcDNA3-HA-GCN5 (Y260A/F261A) and
cloned into a pASK-IBA37 vector in frame with c.o. IN.
The sequence encoding TEV protease recognition site
was inserted by PCR between IN and GCN5 cDNAs.
pGIPZ and pGIPZGCN5 lentiviral vectors were pur-
chased from Open Biosystems (Huntsville, AL). The
sequence of GCN5 shRNAmir inserted into the
p G I P Z G C N 5v e c t o ri sa sf o l l o w s :5 ’-CCCATTCATT
CCCTGGCATTAATAGTGAAGCCACAG ATGTATT
AATGCCAGGGAATGAATGGT-3’. For production of
the pGIPZGCN5 mut vector, four point mutations were
introduced in the shRNAmir cassette of pGIPZGCN5,
obtaining the following sequence: 5’-CCCATTCAAA
GGCTGGCA TTAATAGTGAAGCCACAGATGTATT
AATGCCAGCCTTTGAATGGT-3’, where mutated
nucleotides are underlined.
The NL4.3-Luc env-deleted virus expressing the luci-
ferase reporter gene was produced from the pNL4.3.Luc.
R-E- molecular clone obtained from the AIDS Research
and Reference Reagent Program, Division of AIDS,
NIAID, NIH. IN sequence was subcloned from the mole-
cular clone pHXB2 for construction of pNL4.3.Luc.R-E-/
IN WT and pNL4.3/IN WT plasmids. The IN mutations
in pNL4.3.Luc.R-E-/IN K264,266,273R, pNL4.3.Luc.R-E-/
IN K258,264,266,273R and in pNL4.3/IN K264,266,273R,
pNL4.3/IN K258,264,266,273R were introduced by PCR-
based site-directed mutagenesis using either pNL4.3.Luc.
R-E-/IN WT or pNL4.3/IN WT as template.
The envelope plasmid pMDG and the packaging plas-
mid pCMVΔR8.91 were kindly provided by Z. Debyser.
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HAT assays were performed as previously described [1],
with minor modifications. Briefly, GST or 6× His-tag
fusion proteins were incubated with GST-GCN5 and
[
14C]-acetyl-CoA in HAT buffer (50 mM Tris-HCl, pH
8.0, 5% glycerol, 0.1 M EDTA, 50 mM KCl and 2 mM
sodium butyrate) in a final volume of 30 μlf o r4 5m i n
at 30°C. Acetylated proteins were visualized by phos-
phoimaging (Cyclone) after separation by SDS-PAGE.
In vitro binding assay
[
35S]-labeled IN proteins used for in vitro binding assays
were produced from the corresponding pcDNA3-HA
plasmids by using the TNT Reticulocyte Lysate System
(Promega Corp., Madison, WI). Analysis of in vitro
binding between GST fusion proteins and [
35S]-IN or
[
35S]-IN fragments was performed as previously
described [1]. Briefly, GST fusion proteins (1 μg) immo-
bilized on agarose beads, after pre-treatment in a solu-
tion containing DNase I 0.25 U/μl and RNase H 0.25 U/
μl, were incubated with 600 c.p.m. of in vitro translated
[
35S]-proteins in a solution containing 0.2 mg/ml ethi-
dium bromide. Following extensive washes, the reaction
mixtures were resolved by SDS-PAGE and radiolabeled
proteins visualized by phosphoimaging (Cyclone).
Recombinant proteins production and proteolytic
processing
GST fusion proteins were expressed and purified from
Escherichia Coli BL21 as already described [1].
N-terminal 6× His-tagged IN proteins were expressed
in Escherichia Coli BL21 and purified by metal ion affi-
nity chromatography (BD TALON Metal Affinity Resin,
BD Biosciences, Palo Alto, CA) according to a pre-
viously reported protocol [42]. Proteolytic processing of
IN-GCN5 chimeras was performed by incubating 20 μg
of fusion protein with 30 U of TEV protease (AcTEV
Protease, Invitrogen, Inc., Carlsbad, CA) in a buffer con-
taining 50 mM Tris-HCl, pH 8.0, 0.5 mM EDTA, 0.1 M
NaCl, 1 mM DTT and 10% glycerol, overnight at 4°C.
6× His-tagged IN was then recovered from the reaction
mixture by adsorption on BD TALON Resin.
Immunoprecipitation and Western blotting
For immunoprecipitation, cell pellets were lysed 36
hours after transfection in RIPA buffer (50 mM Tris-
HCl, pH 7.5, 150 mM NaCl, 1% Triton X-100, 0.1%
SDS, 0.5% deoxycolic acid) containing 10 mM sodium
butyrate (Sigma, Inc.) and protease inhibitors (Complete
Protease Inhibitor Cocktail Tablets, Roche Diagnostics).
Anti-Flag M2 affinity resin or rat monoclonal anti-HA
antibody were incubated overnight at 4°C with the cell
lysates (2 mg for coimmunoprecipitation or 4 mg for in
vivo acetylation experiments). The HA-immune
complexes were precipitated by incubation with Ultra-
Link Immobilized Protein G (Pierce Biotechnology, Inc.,
Rockford, IL). The precipitated complexes were then
extensively washed and analyzed by Western blotting
using the appropriate antibodies.
Antibodies
The following primary antibodies were used: rabbit anti-
acetylated-lysine (Cell Signaling Technology, Inc., Dan-
v e r s ,M A ) ;m o u s ea n t i - F l a gM 2( S i g m a ,I n c . ,S tL o u i s ,
MO), either free or bound to agarose beads; rat anti-HA
Clone 3F10 (Roche Diagnostics, Indianapolis, IN);
mouse anti-IN 8G4, obtained from the AIDS Research
and Reference Reagent Program; rabbit anti-GCN5 H-75
(Santa Cruz Biotechnology, Inc., Santa Cruz, CA) and
mouse anti-a-tubulin Clone B-5-1-2 (Sigma, Inc.).
For the production of a polyclonal, anti-acetylated IN
antibody, three rabbits were immunized with a peptide
corresponding to amino acids 261-280 of the IN
sequence, chemically acetylated at lysines 264, 266 and
273, after conjugation with Maleimide Activated
mcKLH (Pierce Biotechnology, Inc.). The IgG fraction
was obtained from collected sera with the use of Immu-
noPure (A) IgG Purification Kit (Pierce Biotechnology,
Inc.). The purified samples were then passed over a col-
umn conjugated with the unmodified IN peptide to
remove the antibody cross-reacting with non-acetylated
IN.
Secondary horseradish peroxidase (HRP)-conjugated
antibodies against mouse or rabbit Igs were purchased
by Santa Cruz Biotechnology, Inc. For Western blot ana-
lysis with anti-acetylated-lysine antibody, Biotin-SP-con-
jugated AffiniPure F(ab’)2 Fragment Donkey Anti-Rabbit
IgG (H+L) (Jackson ImmunoResearch Laboratories, Inc.,
West Grove, PA) and ECL Streptavidin-HRP conjugate
(Amersham Biosciences Corp., Piscataway, NJ) were
employed.
Cell cultures and virus production
HeLa and HEK 293T cells were cultured in DMEM sup-
plemented with 10% fetal calf serum (FCS), 100 U/ml
penicillin and 100 μg/ml streptomycin. HEK 293T cells
stably transduced with pGIPZ vectors were grown with
the addition of puromycin 2 μg/ml. CEM cells were cul-
tured in RPMI 1640 supplemented with 10% FCS,
2 mM glutamine, 100 U/ml penicillin and 100 μg/ml
streptomycin.
To produce env-deleted, VSV-G pseudotyped NL4.3-
Luc viruses, 6× 10
6 HEK 293T cells were transfected
with 20 μg of pNL4.3.Luc.R-E- (wild-type or mutated)
and 5 μg of the envelope plasmid pMDG using the PEI
reagent (Sigma, Inc.). The cell culture supernatant was
collected 48 h after transfection and filtered through a
0.45 μM pore size filter.
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described for NL4.3-Luc viral clones, using 25 μgo f
pNL4.3 plasmid (wild-type or mutated) for transfections.
For the generation of viral vector stocks, HEK 293T
cells were transfected with 10 μgo ft h ep a c k a g i n gp l a s -
mid pCMVΔR8.91, 5 μgo fp M D Ga n d2 0μgo ft h e
gene transfer plasmid (pGIPZ, pGIPZGCN5, or
pGIPZGCN5 mut), following the protocol used for virus
production. The cell culture supernatant was collected
twice, at 48 h and 72 h after transfection, filtered
through a 0.45 μM pore size filter and concentrated by
ultracentrifugation at 110000 × g for 2 h at 4°C.
Both viruses and viral vectors were titered by quantifi-
cation of p24 antigen in cell culture supernatants with
an enzyme-linked immunoabsorbent assay (Innoge-
netics, Gent, Belgium).
Transient and stable knockdown of GCN5 expression
GCN5-targeting siRNA (Dharmacon Research, Boulder,
CO) had the following plus-strand sequence: 5’-AAC-
CAUGGAGCUGGUCAAUGAAA-3’. As a non-silencing
control, Dharmacon ON-TARGETplus siCONTROL
Non-Targeting Pool was employed.
HeLa cells, seeded in 6-well plates (1.5 × 10
6 cells/well),
were transfected twice at a 24 h interval with 150 nM
siRNA using Gene Silencer reagent as recommended by
the manufacturer (Gene Therapy Systems, Inc., San
Diego, CA). Cells trypsinized after 20 h were either plated
for infections, or lysed for Western blot analysis.
For production of stably silenced cell lines, HEK 293T
cells, seeded in 24-well plates (5 × 10
4 cells/well), were
transduced with shRNAmir-encoding pGIPZ lentiviral
v e c t o r sa n dg r o w ni nm e d i u mc o n t a i n i n g2μg/ml
puromycin.
Infectivity and IN activity assays
For single-round replication assays, siRNA-treated HeLa
cells (2.5 × 10
6/well) or HEK 293T cells (5 × 10
6/well)
were seeded in 6-well plates and incubated for 3 h, in a
total volume of 500 μl, with 50 or 100 ng p24 antigen of
NL4.3-Luc virus (wild type or mutated), respectively.
Cells were collected 48 h after infection for measure-
ment of luciferase activity (Luciferase Assay System,
Promega Corp.).
Viral stocks used in infections for measurement of
HIV-1 DNA species by RT-Q-PCR were pre-treated for
1 h at 37°C with 160 U/ml Turbo DNase (Ambion, Inc.,
Austin, TX).
For multiple-round infections, 1 × 10
6 CEM cells were
incubated with 1 ng or 10 ng p24 antigen of NL4.3
virus (wild-type or mutated) in a total volume of 500 μl
for 3 h. Every 3 days, supernatants were collected and
viral titers determined by a
32P-based RT assay per-
formed by standard procedures.
To evaluate IN catalytic activity in vitro,3 ’-end pro-
cessing and strand transfer reactions were performed
with recombinant IN proteins as previously described
[1].
Real-time quantitative PCR analysis
Total DNA was extracted from HEK 293T cells with the
DNeasy Tissue Kit (QIAGEN, Valencia, CA) at different
time points after infection. Amplification reactions were
performed with the Light Cycler 480 instrument (Roche
Diagnostics). Quantification of total HIV-1 DNA was
performed with a pair of primers and a fluorogenic
hybridization probe annealing to the luciferase reporter
gene of NL4.3-Luc viral clone. The sequences of the pri-
mers and the probe are as follows: forward primer,
LucFw, 5’-GAAGAGATACGCCCTGGTTCC-3’;r e v e r s e
primer, LucRev, 5’-TGTGATTTGTATTCAGCCCA-
TATCG-3’;a n dp r o b e ,L u c P r o b e ,5 ’-FAM-TTCA-
TAGCTTCTGCCAACCGAACGGACA-3’ -B l a c k B e r r y
Quencher. Reaction mixtures contained 500 ng of total
genomic DNA, 1× Light Cycler 480 Probe Master
(Roche Diagnostics), 300 nM each forward and reverse
primers and 200 nM probe in a total volume of 20 μl.
After an initial denaturation step (95°C for 10 min), the
cycling profile was 40 cycles consisting of 95°C for 30 s,
60°C for 30 s, and 72°C for 30 s. Quantifications of pro-
viral DNA at 48 h post infection (Alu-LTR nested PCR)
and of two-LTR circles were performed according to
previously described protocols [43]. For detection of
integrated HIV-1 DNA in HEK 293T cells transduced
with pGIPZ vectors, cells were maintained in culture for
two weeks and proviruses were quantified using LucFw,
LucRev primers and LucProbe.
As an internal standard for normalizing the amount of
cellular genomic DNA, the level of human b-globin
DNA was determined in each sample using primers and
fluorogenic hybridization probe that were previously
described [44]. The amplification conditions included a
hot start at 50°C for 2 min and 95°C for 10 min, fol-
lowed by 40 cycles of denaturation at 95°C for 15 s and
extension at 60°C for 1 min.
Statistical analysis
Paired comparisons were carried out using two-tailed
Student’s t-tests, assuming equal variance between sam-
ples to determine differences at the 5% level; all data
points (including outliers) were included in the analysis
for significance.
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